Reversine induces autophagic cell death through the AMP-activated protein kinase pathway in urothelial carcinoma cells

被引:15
作者
Fang, Chiung-Yao [1 ]
Chen, Jeng-Sheng [3 ]
Chang, Shun-Kai [2 ]
Shen, Cheng-Huang [2 ,4 ]
机构
[1] Chiayi Christian Hosp, Ditmanson Med Fdn, Dept Med Res, Chiayi, Taiwan
[2] Chiayi Christian Hosp, Ditmanson Med Fdn, Dept Urol, Chiayi, Taiwan
[3] Minist Hlth & Welf, Sinying Hosp, Dept Urol, Sinying, Taiwan
[4] Asia Univ, Dept Hlth & Nutr Biotechnol, Taichung, Taiwan
关键词
AMP-activated protein kinase pathway; autophagy; reversine; urothelial carcinoma; AURORA-A KINASE; BLADDER-CANCER; INHIBITOR; AGENTS; OVEREXPRESSION; CHEMOTHERAPY; EXPRESSION; PLASTICITY; INCREASES; TARGETS;
D O I
10.1097/CAD.0000000000000563
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Urothelial carcinoma is one of the most common malignancies of the urinary tract. Effective treatment of advanced urothelial carcinoma remains a clinical challenge with poor outcomes in these patients. Previous reports have shown that the expression of aurora kinase is associated with clinical stage and prognosis; hence, aurora kinases are potential targets in urothelial carcinoma therapy. Reversine, an aurora kinase inhibitor, was analyzed for its cytotoxicity in this study. Cell proliferation, flow cytometry, western blotting, and immunofluorescent assay were used to determine the effect of reversine on urothelial carcinoma cells. The results showed that reversine significantly inhibits the growth of urothelial carcinoma cell lines. Reversine induced cell cycle arrest at the G2/M phase, leading to autophagic cell death by activating the AMP-activated protein kinase pathway. Reversine induced significant cell death in urothelial carcinoma cells. Our results suggest that reversine may be a suitably small molecule for treating urothelial carcinoma in the future. (c) 2017 Wolters Kluwer Health, Inc. All rights reserved.
引用
收藏
页码:29 / 39
页数:11
相关论文
共 40 条
[1]   Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends [J].
Antoni, Sebastien ;
Ferlay, Jacques ;
Soerjomataram, Isabelle ;
Znaor, Ariana ;
Jemal, Ahmedin ;
Bray, Freddie .
EUROPEAN UROLOGY, 2017, 71 (01) :96-108
[2]   Aurora-A: the maker and breaker of spindle poles [J].
Barr, Alexis R. ;
Gergely, Fanni .
JOURNAL OF CELL SCIENCE, 2007, 120 (17) :2987-2996
[3]   Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up [J].
Bellmunt, J. ;
Orsola, A. ;
Leow, J. J. ;
Wiegel, T. ;
De Santis, M. ;
Horwich, A. .
ANNALS OF ONCOLOGY, 2014, 25 :40-48
[4]   A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers [J].
Bischoff, JR ;
Anderson, L ;
Zhu, YF ;
Mossie, K ;
Ng, L ;
Souza, B ;
Schryver, B ;
Flanagan, P ;
Clairvoyant, F ;
Ginther, C ;
Chan, CSM ;
Novotny, M ;
Slamon, DJ ;
Plowman, GD .
EMBO JOURNAL, 1998, 17 (11) :3052-3065
[5]  
Bufo P, 2010, HISTOL HISTOPATHOL, V25, P1371, DOI 10.14670/HH-25.1371
[6]   The cellular geography of aurora kinases [J].
Carmena, M ;
Earnshaw, WC .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2003, 4 (11) :842-854
[7]   Making the Auroras glow: regulation of Aurora A and B kinase function by interacting proteins [J].
Carmena, Mar ;
Ruchaud, Sandrine ;
Earnshaw, William C. .
CURRENT OPINION IN CELL BIOLOGY, 2009, 21 (06) :796-805
[8]   Emerging therapeutic targets in bladder cancer [J].
Carneiro, Benedito A. ;
Meeks, Joshua J. ;
Kuzel, Timothy M. ;
Scaranti, Mariana ;
Abdulkadir, Sarki A. ;
Giles, Francis J. .
CANCER TREATMENT REVIEWS, 2015, 41 (02) :170-178
[9]   Reversine increases the plasticity of lineage-committed mammalian cells [J].
Chen, Shuibing ;
Takanashi, Shinichi ;
Zhang, Qisheng ;
Xiong, Wen ;
Zhu, Shoutian ;
Peters, Eric C. ;
Ding, Sheng ;
Schultz, Peter G. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (25) :10482-10487
[10]   Aurora kinase inhibitor patents and agents in clinical testing: an update (2011-2013) [J].
Cheung, Chun Hei Antonio ;
Sarvagalla, Sailu ;
Lee, Jane Ying-Chieh ;
Huang, Yi-Chun ;
Coumar, Mohane Selvaraj .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2014, 24 (09) :1021-1038